Key points from article :
Immunethep is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria.
Has received a grant from Bill & Melinda Gates Foundation to assess if orally delivered anti-GAPDH antibodies can prevent group B streptococcus infections.
Reinforces the company's confidence in the scientific platform behind its pipeline - Pedro Madureira, CSO.
